Shaker Investments LLC OH Cuts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Shaker Investments LLC OH reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 44,658 shares of the medical equipment provider’s stock after selling 145 shares during the period. Lantheus makes up about 1.7% of Shaker Investments LLC OH’s holdings, making the stock its 16th largest position. Shaker Investments LLC OH’s holdings in Lantheus were worth $3,995,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus during the 3rd quarter worth about $25,000. Signaturefd LLC boosted its position in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the last quarter. UMB Bank n.a. raised its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. purchased a new position in shares of Lantheus during the 3rd quarter worth $51,000. Finally, GAMMA Investing LLC grew its position in shares of Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.50% of the company’s stock.

Lantheus Trading Down 2.0 %

Shares of NASDAQ:LNTH opened at $86.91 on Tuesday. Lantheus Holdings, Inc. has a 12-month low of $54.69 and a 12-month high of $126.89. The firm has a market cap of $6.04 billion, a PE ratio of 14.46 and a beta of 0.44. The company has a fifty day simple moving average of $92.02 and a 200 day simple moving average of $98.46.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on LNTH shares. The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $131.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.